1. Synagis® (palivizumab). European Summary of Product Characteristics. Ludwigshafen, Germany: AbbVie Deutschland GmbH & Co.; 2009.

2. Goldstein M, Phillips R, DeVincenzo JP, et al. National Perinatal Association 2018 Respiratory Syncytial Virus (RSV) Prevention Clinical Practice Guideline: an evidence-based interdisciplinary collaboration. Neonatology Today. 2017;12:1-27

3. Rossi GA, Colin AA. Infantile respiratory syncytial virus and human rhinovirus infections: respective role in inception and persistence of wheezing. Eur Respir J. 2015;45(3):774-789. doi:10.1183/09031936.00062714

4. Lu B, Liu H, Tabor DE, et al. Emergence of new antigenic epitopes in the glycoproteins of human respiratory syncytial virus collected from a US surveillance study, 2015-17. Sci Rep. 2019;9(1):3898. doi:10.1038/s41598-019-40387-y

5. Resch B. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection. Hum Vaccin Immunother. 2017;13(9):2138-2149. doi:10.1080/21645515.2017.1337614

6. Piedimonte G, Perez MK. Respiratory syncytial virus infection and bronchiolitis. Pediatr Rev. 2014;35(12):519-530. doi:10.1542/pir.35- 12-519

7.  WHO strategy to pilot global respiratory syncytial virus surveillance based on the Global Infl uenza Surveillance and Response System (GISRS). World Health Organization. 2017. Accessed July 27, 2020. https://www.who.int/influenza/rsv/WHO_RSV_pilot_strategy_21112017.pdf

8. European Lung Foundation. Preterm birth and the lungs. Accessed June 22, 2020. https://www.europeanlung.org/assets/files/en/publications/preterm-en.pdf

9. Sommer C, Resch B, Simões EA. Risk factors for severe respiratory syncytial virus lower respiratory tract infection. Open Microbiol J. 2011;5(suppl2-M4):144-154. doi:10.2174/1874285801105010144

10. Greenspan JS. Bronchopulmonary dysplasia (BPD). KidsHealth from Nemours. Updated October 2014. Accessed June 24, 2020. https://kidshealth.org/en/parents/bpd.html

11. Chaw SP, Hua L, Cunningham S, Campbell H, Mikolajczyk R, Nair H; RESCEU Investigators. Respiratory syncytial virus-associated acute lower respiratory infections in children with bronchopulmonary dysplasia: systematic review and meta-analysis. J Infect Dis. doi:10.1093/infdis/jiz492

12. Use of palivizumab in children with congenital heart disease. Paediatr Child Health. 2003;8(10):631-633.

13. Shi T, McAllister DA, O’Brien KL, et al; RSV Global Epidemiology Network. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946-958. doi:10.1016/S0140-6736(17)30938-8

14. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk Infants. Pediatrics. 1998;102(3):531-537.
doi:10.1542/peds.102.3.531

15. Feltes TF, Cabalka AK, Meissner HC, et al; Cardiac SYNAGIS Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically signifi cant congenital heart disease. J Pediatr. 2003;143(4):532-540. doi:10.1067/s0022-3476(03)00454-2

16. Data on File. AstraZeneca Veeva Approval ID: REF-94356.

NS ID XL-2155-Revision date 07/2021-WEBLocal code 935